[Edaily Reporter YU JIN-HEE ] #SANIGEN Co., Ltd., a molecular diagnostics company specializing in microorganisms, has filed a patent for proprietary technology capable of detecting the dengue virus in just one hour, marking the official launch of its push into the global human molecular diagnostics market, valued at 1.3 trillion won.
SANIGEN Co., Ltd. announced on the 17th that it had completed the filing of a patent application with the Korean Intellectual Property Office for a “primer set capable of detecting the dengue virus and a single-step reverse transcription polymerase chain reaction (RT-PCR) kit containing the same.” SANIGEN Co., Ltd. plans to incorporate this core technology into its new lineup of human molecular diagnostic products and proceed with commercialization.
(Photo: SANIGEN Co., Ltd.)
Dengue fever, a mosquito-borne disease, is a deadly infectious disease that infects 390 million people and claims approximately 7,000 lives annually. In particular, the high rate of asymptomatic infection—ranging from 50% to 80%—makes it extremely difficult to contain the spread in its early stages. According to market research firm Straits Research, the global dengue fever diagnostics market is projected to grow rapidly from 900 billion won this year to 1.3 trillion won by 2034.
The core of this patent is real-time polymerase chain reaction (Real-time PCR) technology, which reverse-transcribes and amplifies the dengue virus in a single step to enable highly sensitive and precise analysis within one hour. Given that dengue fever’s high rate of asymptomatic cases leads to a sharp rise in fatality rates if initial response is delayed, the company explains that securing the “golden time” for diagnosis can dramatically improve patient survival rates.
SANIGEN Co., Ltd. is rapidly expanding the unique technological capabilities it has built up in the fields of food and microbiological diagnostics into the human diagnostics sector. To date, the company has filed a total of 45 industrial property rights applications domestically and internationally, with 42 of these patents already registered; it has also filed and registered seven applications under the Patent Cooperation Treaty (PCT). The company has also demonstrated the technical reliability of its technology through joint research with government agencies, such as the Ministry of Food and Drug Safety, and university industry-academia cooperation centers.
The company plans to use this patent as a starting point to proactively secure core intellectual property (IP) rights for various viral groups and build a portfolio of future growth engines.
Park Jeong-woong, CEO of SANIGEN Co., Ltd., stated, “This patent application proves that SANIGEN Co., Ltd.’s molecular diagnostic technology is fully competitive in the field of human diagnostics as well,” adding, “Building on our proven technological capabilities, we will proactively secure key patents for various infectious diseases and emerge as an innovative biotech company in the global human diagnostics market.”
SK hynix has developed a 122-terabyte (TB) ultra-high-capacity solid-state drive (SSD) for use in artificial intelligence (AI) data centers and has begun supplying samples to customers. Amid growing d…
#SANIGEN Co., Ltd., a molecular diagnostics company specializing in microorganisms, has filed a patent for proprietary technology capable of detecting the dengue virus in just one hour, marking the of…
With the U.S. government introducing export control regulations that block Chinese companies from accessing overseas data centers via workarounds, changes are expected in the global competition to att…